Critical Appraisal of Effectiveness of Oral Fingolimod on Relapsing Multiple Sclerosis

Abstract

Oral fingolimod has been recently accepted as a treatment for relapsing Multiple Sclerosis (MS) by the Indonesian Food and Drug Administration. The number of MS patients is increasing in Indonesia. There is a critical need of systematically reviewing the new medication for